Last reviewed · How we verify
Elcelyx Therapeutics, Inc. — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Met DR | Met DR | marketed | ||||
| Met IR | Met IR | marketed | Biguanide | AMP-activated protein kinase (AMPK) | Endocrinology / Diabetes |
Therapeutic area mix
- Endocrinology / Diabetes · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Bristol-Myers Squibb · 1 shared drug class
- Daewoong Pharmaceutical Co. LTD. · 1 shared drug class
- Eli Lilly and Company · 1 shared drug class
- Ente Ospedaliero Ospedali Galliera · 1 shared drug class
- First Affiliated Hospital of Wenzhou Medical University · 1 shared drug class
- GlaxoSmithKline · 1 shared drug class
- Janssen Research & Development, LLC · 1 shared drug class
- AstraZeneca · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Elcelyx Therapeutics, Inc.:
- Elcelyx Therapeutics, Inc. pipeline updates — RSS
- Elcelyx Therapeutics, Inc. pipeline updates — Atom
- Elcelyx Therapeutics, Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Elcelyx Therapeutics, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/elcelyx-therapeutics-inc. Accessed 2026-05-16.